Fairbanks Wins Boston Innovation Prize “Golden Ticket”

Fairbanks Pharmaceuticals wins 2018 Boston Innovation Award
Fairbanks CEO Dr. Alan Schneyer (center) receives the award from Dr. Clive Wood, BI Senior Vice President of Discovery Research (right) and Dr. Jannis Sapountzis, BI US Head of Business Development and Licensing (left)

Boehringer Ingelheim (BI) and the BI Venture Fund have awarded Fairbanks Pharmaceuticals the prestigious 2018 Boston Innovation Prize “Golden Ticket.”  The prize recognizes the challenge and dedication it takes to successfully build a new  company by supporting the innovation process and celebrating life-science entrepreneurs.  The award, worth up to $75,000, includes one year of rent at the LabCentral facility in Cambridge, MA.  Dr. Clive Wood, Senior Vice President of Discovery Research at BI, presented the award to Dr. Alan Schneyer, Fairbanks’ CEO.

LabCentral is a first-of-its kind shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups.  As a testament to its success, in recent years, LabCentral residents and alumni have raised over two billion dollars, with over $750 million dollars in financing in 2017 alone.  

Fairbanks Pharmaceuticals was chosen from a field of ten early-stage bioscience organizations that presented their pitches to a panel of judges.  “We are honored to have been selected by BI as the best young biotech company and we greatly appreciate the validation of our idea and approach by such a distinguished pharmaceutical company” said Dr. Schneyer.  Dr. Schneyer said that he and his team are excited for the opportunity to locate in Lab Central in Cambridge, the center of biotech entrepreneurism.  Fairbanks is also looking forward for the opportunity to work more closely with BI scientists to facilitate development of our lead candidates.